These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28581634)

  • 61. Retreatment of a treatment-experienced patient with genotype 6 hepatitis C virus infection: follow-up on a reported case.
    Spooner LM; Abraham GM
    Am J Health Syst Pharm; 2015 Jan; 72(1):14-6. PubMed ID: 25511831
    [No Abstract]   [Full Text] [Related]  

  • 62. Viral hepatitis C treatment shortening - what is the limit?
    Zarębska-Michaluk D
    Clin Exp Hepatol; 2019 Nov; 5(4):265-270. PubMed ID: 31893236
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    Falade-Nwulia O; Sulkowski MS
    J Infect Dis; 2020 Nov; 222(Suppl 9):S745-S757. PubMed ID: 33245350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Tovar Pozo M; García-Cabrera E; Monje García B; Tutau Gómez F; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Dec; 41(6):1545-1554. PubMed ID: 31650508
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Importance of adherence to treatment with direct-acting antivirals in hepatitis C.
    Monte-Boquet E; Verdugo RM; Navarro H; Quer JC; Ventayol P
    Gastroenterol Hepatol; 2019 Sep; 42 Suppl 1():14-19. PubMed ID: 32560768
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Perspective: recognizing resistance.
    Sylvestre D
    Nature; 2011 Jun; 474(7350):S11. PubMed ID: 21666727
    [No Abstract]   [Full Text] [Related]  

  • 67. What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment.
    Evon DM; Golin CE; Stoica T; Jones RE; Willis SJ; Galanko J; Fried MW
    Patient; 2017 Jun; 10(3):335-344. PubMed ID: 27882509
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.
    Goyal A; Churkin A; Barash D; Cotler SJ; Shlomai A; Etzion O; Dahari H
    Open Forum Infect Dis; 2022 May; 9(5):ofac157. PubMed ID: 35493122
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Programs for Continuing Medical Education: A session; 1. New therapeutic strategies for hepatitis C by direct-acting antivirals (DAA)].
    Sakamoto N
    Nihon Naika Gakkai Zasshi; 2016 Mar; 105(3):424-8. PubMed ID: 27319187
    [No Abstract]   [Full Text] [Related]  

  • 70. Short duration of direct-acting antivirals for acute HCV infection.
    Yu ML
    Lancet Infect Dis; 2017 May; 17(5):481-482. PubMed ID: 28447953
    [No Abstract]   [Full Text] [Related]  

  • 71. [Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease].
    Chung WJ
    Korean J Gastroenterol; 2016 Jan; 67(1):58-60. PubMed ID: 27213201
    [No Abstract]   [Full Text] [Related]  

  • 72. Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost.
    Wong JB; Cohen JT
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):838-840. PubMed ID: 28259743
    [No Abstract]   [Full Text] [Related]  

  • 73. Viral hepatitis: Response-guided strategy to reduce DAA duration for hepatitis C.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):558. PubMed ID: 27625193
    [No Abstract]   [Full Text] [Related]  

  • 74. The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?
    Younossi ZM
    Clin Liver Dis (Hoboken); 2015 Nov; 6(5):126-128. PubMed ID: 31041007
    [No Abstract]   [Full Text] [Related]  

  • 75. Shortening Treatment for Hepatitis C Virus Infection.
    Kottilil S
    Gastroenterol Hepatol (N Y); 2018 Mar; 14(3):186-188. PubMed ID: 29928163
    [No Abstract]   [Full Text] [Related]  

  • 76. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
    Johnson K; Green PK; Ioannou GN
    J Viral Hepat; 2017 Nov; 24(11):966-975. PubMed ID: 28585416
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH
    Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
    Saadi T; Khoury J
    J Clin Gastroenterol; 2018 Apr; 52(4):353-359. PubMed ID: 28590324
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.
    Doi A; Sakamori R; Tahata Y; Urabe A; Morishita N; Yamada R; Furuta K; Kodama T; Hikita H; Yakushijin T; Ohkawa K; Kaneko A; Imai Y; Tatsumi T; Takehara T
    Hepatol Res; 2017 Dec; 47(13):1438-1444. PubMed ID: 28585404
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.